The role of fluorine in drug design and development is expanding rapidly as we learn more
about the unique properties associated with this unusual element and how to deploy it with …

Matrix metalloproteinases have long been associated with cancer. Clinical trials of small
molecule inhibitors for this family of enzymes however, were spectacularly unsuccessful in a …

Proteases enzymatically hydrolyze peptide bonds in substrate proteins, resulting in a
widespread, irreversible posttranslational modification of the protein's structure and …

Advances in the field of boron chemistry have expanded the application of boron from
material use to medicine. Boron-based drugs represent a new class of molecules that …

In recent decades, dysregulation of proteases and atypical proteolysis have become
increasingly recognized as important hallmarks of cancer, driving community-wide efforts to …

Proteases are well-established targets for pharmaceutical development because of their
known enzymatic mechanism and their regulatory roles in many pathologies. However …

Positron emission tomography (PET) imaging study of fluorine‐18 labeled biomolecules is
an emerging and rapidly growing area for preclinical and clinical research. The present …

The field of 18F chemistry is rapidly expanding because of the use of this radionuclide in
radiotracers for positron emission tomography (PET). Until recently, most [18F]-radiotracers …

Positron emission tomography (PET) is a powerful technique for imaging biological
pathways in vivo, particularly those that are key targets in disease processes. In contrast …

Unorthodox 18F-labeling strategies not employing the formation of a carbon-18F bond are
seldom found in radiochemistry. Historically, the formation of a boron-or silicon-18F bond …